Electro-Magnetic-Frequency Therapy (EMF) for Chronic Fatigue
Not Applicable
Recruiting
- Conditions
- Chronic fatigueViral Reactivation with Epstein-Barr Virus (EBV)Viral Reactivation with Cyto-Megalo-Virus (CMV)Viral Reactivation with Herpes Simplex Virus (HSV)Other - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)Infection - Other infectious diseases
- Registration Number
- ACTRN12624000178549
- Lead Sponsor
- AProf Dr Karin Ried
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
adults with viral reactivated chronic fatigue
Exclusion Criteria
patients with electronic implants, e.g. pacemaker, defi brillator, cochlear implant, ring-shaped metals in thebody
planning to introduce new treatments during the study period
unable to commit to regular treatment sessions over a 3 month period
unable to give consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of CRC/ml by cytology[The CRC blood test combines a) the isolation of Circulating Rare Cells (CRC) from the blood with the ISET-CTC technology (Rarecells, France), cytology, and b) antibody marker testing by Immuno-Cyto-Chemistry. The number of CRC (quantitative) and detection of viral reactivation (qualitative) provides information baout the immune system's capacity to function and manage abnormal / unusual cell. CTC (Circulating Tumour Cells) are a sub-set of CRC without viral reactivation. Day 2, 3 months, 6 months post-commencement of treatment compared to baseline (Day1 before the treatment)]
- Secondary Outcome Measures
Name Time Method Symptom impact questionnaire[Composite score of in-house developed questionnaire used in the Long-COVID study (ACTRN12622001204730p) 3 and 6 months post-commencement of treatment compared to baseline (before treatment Day 1)]